Johan Albrecht to Join 3D Printing Software & Services Company Materialise as CFO
As the 3D printing industry and all the large players within it continues to expand and evolve, the financial well-being of these companies as they compete to stay on top is a necessity. With sweeping changes being made within some of the larger 3D printing corporations, Belgium’s Materialise (NASDAQ:MTLS) has remained rather quiet when it comes to employee turnover. This all changed though when the company’s current Chief Financial Officer, Frederick Merckx, notified the company’s board back in May that he would be resigning to pursue other career opportunities.
Up until today Materialise, a leader within the 3D printing software and services space, had not announced a replacement for one of their most important positions. Today, however, that announcement came with John Albrecht ready to step in and take over the financial reins of the company.
“We are delighted to welcome Johan to the Materialise team,” stated Executive Chairman of Materialise Peter Leys. “With three decades of experience in finance in an international business environment, Johan is uniquely suited to Materialise. His accomplishments include facilitating BARC’s successful transition in 2007 from a family-owned enterprise to a company with a majority ownership by private equity. Johan’s proven capabilities will help us continue the momentum we have established since becoming a public company last year and leverage the many high-growth opportunities in the 3D printing market worldwide.”
Albrecht seems like he may be a perfect for for the position as he has over 30 years of experience working in roles requiring financial expertise. Way back in 1984, his career began when he took on the role of Financial Analyst at a
company called Minit International. From there Albrecht moved on to serve in varying financial capacities for companies within the data research as well as food services industries. Most importantly though, Albrecht has served the last 26 years as the CFO of BARC NV, a central laboratory which supports the biotech and pharmaceutical industries in developing new treatments and drugs. In this role he was responsible for control systems as well as worldwide business and financial reporting.
Albrecht will join Materialise starting tomorrow, July 7, and move into his role as CFO in about 5 weeks on August 12. It will be interesting to see if anything changes from a financial standpoint once he is put into control.
Let’s hear your thoughts on this recent appointment by Materialise, and what it could ultimately mean for the company. Discuss in the Johan Albrecht forum thread on 3DPB.om.
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
Print Services
Upload your 3D Models and get them printed quickly and efficiently.
You May Also Like
Printing Money Episode 38: Additive Manufacturing Deal Analysis with Rajeev Kulkarni
Welcome to Printing Money Episode 38. Rajeev Kulkarni returns for this episode, and we find it hard to believe it’s been nearly two years since his first appearance. In the interim,...
3D Printing News Briefs, May 14, 2026: Project Calls, Reseller, Reconstructive Surgery, & More
We’re starting off today’s 3D Printing News Briefs with two new Project Calls from America Makes. We’ll move on to some more business, with Axtra3D expanding its presence in North...
Fabric8Labs & University of Illinois Collaborate on 3D Printed Copper Cold Plates for Data Centers
Collaboration between emerging technology enterprises and research universities is one of the most consistently winning tactics for any nation building (or rebuilding) an industrial ecosystem. It’s an especially constructive approach...
3D Printing News Briefs: May 7, 2026: Metal Powder Bed Fusion, Surgical Plates, & More
In today’s 3D Printing News Briefs, we’ll start with a strategic collaboration to advance next-generation metal additive manufacturing (AM), before moving on to funding for surgical research. We’ll end with...





































